24/7 Patient Assistance: 760-405-8205

Pamela Munster, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information

    Dr. Pamela Munster graduated from the University of Bern Faculty of Medicine. She did her residency program at the Indiana University School of Medicine and also completed a fellowship at the Memorial Sloan-Kettering Cancer Center. She is a board-certified medical oncologist and currently practices at the UCSF Medical Center and San Francisco General Hospital, San Francisco, California. She has also contributed to several research publications.



  • Education & Training

    dept_icon

    University of Bern Faculty of Medicine

    Medical School

    dept_icon

    Indiana University School of Medicine

    Residency

    dept_icon

    Memorial Sloan-Kettering Cancer Center

    Fellowship

  • Board Certifications

    American Board of Internal Medicine

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    San Francisco General Hospital

    Languages: English/Spanish

    (415) 206-8000

    1001 Potrero Ave

    San Francisco, California 94110

    Read More

    UCSF Medical Center

    Languages: English/Spanish

    (415) 353-1037

    505 Parnassus Ave

    San Francisco, California 94143

    Read More
  • Publications & Memberships

    Dr. Pamela Munster has contributed to 3 publications.

    A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.

    Thomas, S.,Aggarwal, R.,Jahan, T.,Ryan, C.,Troung, T.,Moore Cripps, A.,Raha, P.,Thurn, K. T.,Chen, S.,Grabowsky, J. A.,Park, J.,Hwang, J.,Daud, A.,Munster, P. N.; Ann. Oncol.. 2016 Feb 24.

    See more >>

    A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

    Chien, A. J.,Cockerill, A.,Fancourt, C.,Schmidt, E.,Moasser, M. M.,Rugo, H. S.,Melisko, M. E.,Ko, A. H.,Kelley, R. K.,Korn, W. M.,Esserman, L. J.,Van't Veer, L.,Yau, C...; Breast Cancer Res. Treat.. 2016 Feb 15.

    See more >>

    Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen resistant breast cancer models, by reversing Bcl-2 overexpression.

    Raha, P.,Thomas, S.,Thurn, K. T.,Park, J.,Munster, P. N.; Breast Cancer Res.. 2015 Mar 18.

    See more >>